Rate My Professor Danielle Bond

Dr Danielle Bond is an Early Career Researcher, Lecturer, and Casual Academic in the School of Biomedical Sciences and Pharmacy at the University of Newcastle, based at the Hunter Medical Research Institute and associated with the Hunter Cancer Research Alliance. Her research focuses on epigenetic changes in cancer patients following drug treatment, the role of tumour microenvironments in prognosis, treatment response, and resistance, and single-cell analyses of DNA methylation and gene expression in leukaemia. She completed her PhD in medical biochemistry at the University of Newcastle in 2015, investigating post-transcriptional regulation of tetraspanins CD151 and CD9 by microRNAs in breast and prostate cancers. From 2015 to 2017, she served as a Research Associate and Assistant in the Faculty of Science, testing novel natural and synthetic compounds, including Vietnamese medicinal plant extracts, as anti-pancreatic cancer agents and studying blood markers for prostate cancer at the Ourimbah campus. In 2018, she joined the Cancer Epigenetics group led by Dr Heather Lee as a postdoctoral scientist, employing advanced single-cell sequencing to identify markers predicting patient prognosis and therapy response.

Dr Bond earned her Bachelor of Biomedical Sciences with First Class Honours from the University of Newcastle. Her interests include acute myeloid leukaemia, DNA methylation, epigenetics, myelodysplastic syndromes, pancreatic cancer, prostate cancer, tetraspanins, microRNAs, and multi-omics in cancer genetics. Key publications feature 'Hypomethylating agents induce epigenetic and transcriptional heterogeneity in myeloid malignancies' (2025), 'Upregulated cholesterol biosynthesis facilitates the survival of hypomethylating agent-resistant leukaemia cells' (2024), 'scTEM-seq: Single-cell analysis of transposable element methylation...' (2022), and 'The Olive Biophenols Oleuropein and Hydroxytyrosol Selectively Reduce Proliferation... in Pancreatic Cancer Cells' (2018). She has secured a Faculty of Health and Medicine pilot grant, HMRI CFMEU donor grant, and HMRI Leukaemia Donor Grant (2018). Dr Bond has presented at national and international conferences, published in high-impact journals, served as RHD representative on the school research committee, deputy convenor of the ASMR Newcastle committee, and organised local scientific meetings, while building an independent research program on cancer epigenetic heterogeneity.